PMID- 20457135
OWN - NLM
STAT- MEDLINE
DCOM- 20100719
LR  - 20220310
IS  - 1873-2968 (Electronic)
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 80
IP  - 5
DP  - 2010 Sep 1
TI  - Potential therapeutic implications of cancer stem cells in glioblastoma.
PG  - 654-65
LID - 10.1016/j.bcp.2010.04.035 [doi]
AB  - Glioblastoma is the most common and lethal type of primary brain tumor. Despite 
      recent therapeutic advances in other cancers, the treatment of glioblastomas 
      remains ineffective and essentially palliative. The treatment failure is a result 
      of a number of causes, but we and others have demonstrated that a highly 
      tumorigenic subpopulation of cancer cells called glioblastoma stem cells (GSCs) 
      display relative resistance to radiation and chemotherapy. GSCs also contribute 
      to tumor growth through the stimulation of angiogenesis, which has been shown to 
      be a useful therapeutic target in the treatment of recurrent or progressive 
      malignant gliomas. Cancer stem cells also have been hypothesized as a contributor 
      to systemic metastases. While glioblastomas rarely metastasize beyond the central 
      nervous system, glioblastomas invade into brain structures to prevent surgical 
      cure and GSCs have an extremely invasive phenotype. Collectively, these studies 
      and others suggest that GSCs may be important therapeutic targets not only to 
      achieve cure but even reduce tumor relapse and improve overall survival. Many 
      recent studies suggest that GSCs share core regulatory pathways with normal 
      embryonic and somatic stem cells, but display important distinctions that provide 
      clues into useful treatment targets. The cancer stem cell hypothesis may also 
      modify our approaches in tumor imaging and biomarker development, but clinical 
      validation waits. In this review, we summarize the current understanding of GSC 
      biology with a focus on potential anti-GSC therapies.
CI  - Copyright 2010 Elsevier Inc. All rights reserved.
FAU - Cheng, Lin
AU  - Cheng L
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research 
      Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
FAU - Bao, Shideng
AU  - Bao S
FAU - Rich, Jeremy N
AU  - Rich JN
LA  - eng
GR  - NS054276/NS/NINDS NIH HHS/United States
GR  - NS070315/NS/NINDS NIH HHS/United States
GR  - R01 CA129958-03/CA/NCI NIH HHS/United States
GR  - R01 CA129958-04/CA/NCI NIH HHS/United States
GR  - R01 CA116659-05/CA/NCI NIH HHS/United States
GR  - R01 NS070315-02/NS/NINDS NIH HHS/United States
GR  - CA112958/CA/NCI NIH HHS/United States
GR  - CA116659/CA/NCI NIH HHS/United States
GR  - R01 NS054276-05/NS/NINDS NIH HHS/United States
GR  - R01 CA129958/CA/NCI NIH HHS/United States
GR  - R01 NS070315/NS/NINDS NIH HHS/United States
GR  - R01 CA116659/CA/NCI NIH HHS/United States
GR  - R01 CA116659-06/CA/NCI NIH HHS/United States
GR  - R01 NS070315-01/NS/NINDS NIH HHS/United States
GR  - K02 NS047409/NS/NINDS NIH HHS/United States
GR  - NS047409/NS/NINDS NIH HHS/United States
GR  - R01 NS054276/NS/NINDS NIH HHS/United States
GR  - R01 NS054276-04/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100510
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (MicroRNAs)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Brain Neoplasms/metabolism/pathology/*therapy
MH  - Cell Hypoxia
MH  - Glioblastoma/metabolism/pathology/*therapy
MH  - Humans
MH  - MicroRNAs/genetics
MH  - *Neoplastic Stem Cells
MH  - Signal Transduction
MH  - Transcription Factors/metabolism
PMC - PMC2897968
MID - NIHMS209499
EDAT- 2010/05/12 06:00
MHDA- 2010/07/20 06:00
PMCR- 2011/09/01
CRDT- 2010/05/12 06:00
PHST- 2010/03/05 00:00 [received]
PHST- 2010/04/27 00:00 [revised]
PHST- 2010/04/29 00:00 [accepted]
PHST- 2010/05/12 06:00 [entrez]
PHST- 2010/05/12 06:00 [pubmed]
PHST- 2010/07/20 06:00 [medline]
PHST- 2011/09/01 00:00 [pmc-release]
AID - S0006-2952(10)00336-9 [pii]
AID - 10.1016/j.bcp.2010.04.035 [doi]
PST - ppublish
SO  - Biochem Pharmacol. 2010 Sep 1;80(5):654-65. doi: 10.1016/j.bcp.2010.04.035. Epub 
      2010 May 10.